Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
J Neuroinflammation ; 11: 86, 2014 May 08.
Artigo em Inglês | MEDLINE | ID: mdl-24886419

RESUMO

BACKGROUND: Increasing evidence suggests that inflammation associated with microglial cell activation in the substantia nigra (SN) of patients with Parkinson disease (PD) is not only a consequence of neuronal degeneration, but may actively sustain dopaminergic (DA) cell loss over time. We aimed to study whether the intracellular chaperone heat shock protein 60 (Hsp60) could serve as a signal of CNS injury for activation of microglial cells. METHODS: Hsp60 mRNA expression in the mesencephalon and the striatum of C57/BL6 mice treated with MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) and the Hsp60/TH mRNA ratios in the SN of PD patients and aged-matched subjects were measured. To further investigate a possible link between the neuronal Hsp60 response and PD-related cellular stress, Hsp60 immunoblot analysis and quantification in cell lysates from SH-SY5Y after treatment with 100 µM MPP+ (1-methyl-4-phenylpyridinium) at different time points (6, 12, 24 and 48 hours) compared to control cells were performed. Additional MTT and LDH assay were used. We next addressed the question as to whether Hsp60 influences the survival of TH+ neurons in mesencephalic neuron-glia cultures treated either with MPP+ (1 µM), hHsp60 (10 µg/ml) or a combination of both. Finally, we measured IL-1ß, IL-6, TNF-α and NO-release by ELISA in primary microglial cell cultures following treatment with different hHsp60 preparations. Control cultures were exposed to LPS. RESULTS: In the mesencephalon and striatum of mice treated with MPTP and also in the SN of PD patients, we found that Hsp60 mRNA was up-regulated. MPP+, the active metabolite of MPTP, also caused an increased expression and release of Hsp60 in the human dopaminergic cell line SH-SY5Y. Interestingly, in addition to being toxic to DA neurons in primary mesencephalic cultures, exogenous Hsp60 aggravated the effects of MPP+. Yet, although we demonstrated that Hsp60 specifically binds to microglial cells, it failed to stimulate the production of pro-inflammatory cytokines or NO by these cells. CONCLUSIONS: Overall, our data suggest that Hsp60 is likely to participate in DA cell death in PD but via a mechanism unrelated to cytokine release.


Assuntos
Chaperonina 60/metabolismo , Corpo Estriado/patologia , Neurônios Dopaminérgicos/metabolismo , Intoxicação por MPTP/patologia , Mesencéfalo/patologia , 1-Metil-4-Fenil-1,2,3,6-Tetra-Hidropiridina/farmacologia , Animais , Morte Celular/efeitos dos fármacos , Células Cultivadas , Chaperonina 60/genética , Modelos Animais de Doenças , Dopaminérgicos/farmacologia , L-Lactato Desidrogenase/metabolismo , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Microglia/efeitos dos fármacos , Microglia/metabolismo , Óxido Nítrico/metabolismo , Ligação Proteica/efeitos dos fármacos , RNA Mensageiro/metabolismo , Tirosina 3-Mono-Oxigenase/metabolismo
3.
Brain Res ; 1052(1): 97-104, 2005 Aug 02.
Artigo em Inglês | MEDLINE | ID: mdl-16005444

RESUMO

Oxidative stress is a major contributing factor in the pathogenesis of Parkinson's disease. We therefore investigated the effect of the dopaminergic neurotoxin 6-hydroxydopamine (6-OHDA) on hydroxyl-free radical and peroxynitrite formation in the intrastriatal 6-OHDA rat model of Parkinson's disease. The hydroxylation product of salicylate (2,3-dihydroxy-benzoic acid) as well as the hydroxylation and nitration products of d-phenylalanine (2- and 3-hydroxyl-phenylalanine, nitrotyrosine and nitrophenylalanine) were assessed in tissue samples of the striatum and, for the first time, the substantia nigra of adult rats at four different time points (25 min, 2 h, 4 h and 7 days) after unilateral stereotaxic intrastriatal injection of 6-OHDA. In the striatum, maxima of hydroxylating and nitrating markers were found at early time points after 6-OHDA lesion. These results suggest a direct interrelation between 6-OHDA-autoxidation and/or the increased dopamine turnover and hydroxyl-free radical and peroxynitrite formation. In the substantia nigra, i.e., at a distance from the injection site of the neurotoxin, an increase in hydroxyl-free radical formation was observed at 7 days after 6-OHDA lesion, with this modification possibly being independent of 6-OHDA autoxidation and rather representing a long-term effect of the toxin. Furthermore, we conclude that apart from the formation of reactive oxygen species, the production of reactive nitrogen species occurs in this experimental Parkinson's disease model. Finally, the similarity between the 6-OHDA model and Parkinson's disease supports the notion that reactive oxygen species as well as reactive nitrogen species may play an important role in the pathogenesis of this neurodegenerative disorder.


Assuntos
Adrenérgicos/toxicidade , Corpo Estriado/efeitos dos fármacos , Oxidopamina/toxicidade , Espécies Reativas de Nitrogênio/metabolismo , Espécies Reativas de Oxigênio/metabolismo , Substância Negra/efeitos dos fármacos , Análise de Variância , Animais , Química Encefálica/efeitos dos fármacos , Corpo Estriado/lesões , Corpo Estriado/metabolismo , Lateralidade Funcional , Masculino , Ratos , Ratos Wistar , Substância Negra/lesões , Substância Negra/metabolismo , Fatores de Tempo
4.
Neurosci Lett ; 383(1-2): 44-8, 2005.
Artigo em Inglês | MEDLINE | ID: mdl-15936509

RESUMO

In the present study, we evaluated the potential neuroprotective effect of granulocyte colony-stimulating factor (G-CSF), a hematopoietic growth factor in two different culture models in which dopaminergic (DA) neurons die selectively: first, in a culture model in which death of DA neurons occurs spontaneously and second, in a toxin-based paradigm, the in vitro 1-methyl-4-phenylpyridinium model of PD. In neither of the two models, a treatment with G-CSF, could prevent or halt the progressive neurodegeneration. However, we cannot rule out that G-CSF might exert neuroprotective or even deleterious effects in in vivo models of PD, based on the significant increase in the number of microglial cells observed after G-CSF treatment.


Assuntos
Morte Celular/efeitos dos fármacos , Dopamina/metabolismo , Fator Estimulador de Colônias de Granulócitos/farmacologia , Neurônios/efeitos dos fármacos , 1-Metil-4-fenilpiridínio/toxicidade , Análise de Variância , Animais , Antígeno CD11b/metabolismo , Contagem de Células/métodos , Proliferação de Células/efeitos dos fármacos , Células Cultivadas , Citarabina/toxicidade , Relação Dose-Resposta a Droga , Interações Medicamentosas , Embrião de Mamíferos , Proteína Glial Fibrilar Ácida/metabolismo , Herbicidas/toxicidade , Imuno-Histoquímica/métodos , Microglia/efeitos dos fármacos , Microglia/metabolismo , Proteínas Associadas aos Microtúbulos/metabolismo , Neurônios/citologia , Neurônios/metabolismo , Ratos , Timidina/farmacocinética , Trítio/farmacocinética , Tirosina 3-Mono-Oxigenase/metabolismo , Vimentina/metabolismo
5.
Sci Rep ; 3: 1393, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23462811

RESUMO

In mammalians, toll-like receptors (TLR) signal-transduction pathways induce the expression of a variety of immune-response genes, including inflammatory cytokines. It is therefore plausible to assume that TLRs are mediators in glial cells triggering the release of cytokines that ultimately kill DA neurons in the substantia nigra in Parkinson disease (PD). Accordingly, recent data indicate that TLR4 is up-regulated by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment in a mouse model of PD. Here, we wished to evaluate the role of TLR4 in the acute mouse MPTP model of PD: TLR4-deficient mice and wild-type littermates control mice were used for the acute administration way of MPTP or a corresponding volume of saline. We demonstrate that TLR4-deficient mice are less vulnerable to MPTP intoxication than wild-type mice and display a decreased number of Iba1+ and MHC II+ activated microglial cells after MPTP application, suggesting that the TLR4 pathway is involved in experimental PD.


Assuntos
Transtornos Parkinsonianos/metabolismo , Receptor 4 Toll-Like/metabolismo , 1-Metil-4-Fenil-1,2,3,6-Tetra-Hidropiridina/efeitos adversos , Animais , Morte Celular/genética , Corpo Estriado/metabolismo , Dopamina/metabolismo , Ácido Homovanílico/metabolismo , Camundongos , Camundongos Knockout , Microglia/metabolismo , Transtornos Parkinsonianos/genética , Receptor 4 Toll-Like/genética
6.
Exp Neurol ; 210(1): 182-93, 2008 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-18053987

RESUMO

Genetically modified mice models are increasingly used to study the pathophysiology of Parkinson's disease (PD), particularly in conditions where they are subjected to toxins specific for dopaminergic neurons. The most widely used toxin in these paradigms is 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), although it presents a number of drawbacks regarding (i) the kinetics of neurodegeneration, (ii) strain-specificity and (iii) partial lesion recovery. 6-hydroxydopamine (6-OHDA) may be an alternative tool since it leads to a partial damage of DA terminals and to a delayed and progressive loss of nigral DA neurons. It is frequently used in rats and well characterized in this species. In mice, however, this model has not been described in detail to date. The aim of the present study was to characterize the time course of intra-striatal 6-OHDA lesions in mice with regard to i) dopaminergic cell loss, ii) dopamine concentrations in the substantia nigra and the striatum, iii) hydroxylation products in substantia nigra and striatum and iv) behavioural impairment. Furthermore, we used alpha-synuclein-deleted mice, which have been studied extensively in MPTP paradigms, and examined their reactivity to intra-striatal 6-OHDA injections. Intra-striatally injected 6-OHDA leads to a long-lasting dopamine depletion of the nigro-striatal pathway, whereas behavioural parameters partially recovered over a two month period. Its toxicity seems to be influenced by alpha-synuclein, since alpha-synuclein-deleted mice are more resistant against 6-OHDA than their wild type littermates. In summary, we propose that the striatal 6-OHDA model may be a valuable addition and/or alternative in genetically modified mice models used in the study of PD pathophysiology.


Assuntos
Adrenérgicos/toxicidade , Corpo Estriado/efeitos dos fármacos , Oxidopamina/toxicidade , Doença de Parkinson , alfa-Sinucleína/deficiência , Animais , Comportamento Animal/efeitos dos fármacos , Química Encefálica/efeitos dos fármacos , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Atividade Motora/efeitos dos fármacos , Doença de Parkinson/etiologia , Doença de Parkinson/genética , Doença de Parkinson/fisiopatologia , Teste de Desempenho do Rota-Rod/métodos , Substância Negra/metabolismo , Fatores de Tempo , Tirosina 3-Mono-Oxigenase/metabolismo
7.
Neurobiol Dis ; 23(2): 409-21, 2006 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-16753304

RESUMO

Parkinson's disease (PD) is characterized by loss of dopaminergic (DA) neurons in the human midbrain, which varies greatly among mesencephalic subregions. The genetic expression profiles of mesencephalic DA neurons particularly prone to degenerate during PD (nigrosome 1 within the substantia nigra pars compacta-SNpc) and those particularly resistant in the disease course (central grey substance-CGS) were compared in five control subjects by immuno-laser capture microdissection followed by RNA arbitrarily primed PCR. 8 ESTs of interest were selected for analysis by real time quantitative reverse transcription PCR. DA neurons in the CGS preferentially expressed implicated in cell survival (7 out of 8 genes selected), whereas SNpc DA neurons preferentially expressed one gene making them potentially susceptible to undergo cell death in PD. We propose that factors making CGS DA neurons more resistant may be helpful in protecting SNpc DA neurons against a pathological insult.


Assuntos
Dopamina/análise , Mesencéfalo/patologia , Neurônios/patologia , Doença de Parkinson/patologia , Idoso , Cadáver , Primers do DNA , Perfilação da Expressão Gênica , Humanos , Pessoa de Meia-Idade , Degeneração Neural , Proteínas do Tecido Nervoso/genética , Doença de Parkinson/genética , Reação em Cadeia da Polimerase , RNA/genética , RNA/isolamento & purificação , Valores de Referência
8.
J Neurochem ; 95(4): 1069-77, 2005 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-16135085

RESUMO

There is evidence that an inflammatory microglial reaction participates in the pathophysiology of dopaminergic neuronal death in Parkinson's disease and in animal models of the disease. However, this phenomenon remains incompletely characterized. Using an in vitro model of neuronal/glial mesencephalic cultures, we show that the dopaminergic neurotoxin 1-methyl-4-phenylpyridinium (MPP+) stimulates the proliferation of microglial cells at concentrations that selectively reduce the survival of DA neurones. The mitogenic action of MPP+ was not the mere consequence of neuronal cell demise as the toxin produced the same effect in a model system of neuronal/glial cortical cultures, where target DA neurones are absent. Consistent with this observation, the proliferative effect of MPP+ was also detectable in neurone-free microglial/astroglial cultures. It disappeared, however, when MPP+ was added to pure microglial cell cultures suggesting that astrocytes played a key role in the mitogenic mechanism. Accordingly, the proliferation of microglial cells in response to MPP+ treatment was mimicked by granulocyte macrophage colony-stimulating factor (GM-CSF), a proinflammatory cytokine produced by astrocytes and was blocked by a neutralizing antibody to GM-CSF. Thus, we conclude that the microglial reaction observed following MPP+ exposure depends on astrocytic factors, e.g. GM-CSF, a finding that may have therapeutic implications.


Assuntos
1-Metil-4-fenilpiridínio/toxicidade , Astrócitos/fisiologia , Proliferação de Células/efeitos dos fármacos , Fator Estimulador de Colônias de Granulócitos e Macrófagos/farmacologia , Mesencéfalo/citologia , Microglia/efeitos dos fármacos , Animais , Antígeno CD11c/metabolismo , Contagem de Células/métodos , Células Cultivadas , Relação Dose-Resposta a Droga , Interações Medicamentosas , Embrião de Mamíferos , Imuno-Histoquímica/métodos , Microglia/metabolismo , Proteínas Associadas aos Microtúbulos/metabolismo , Ratos , Tirosina 3-Mono-Oxigenase/metabolismo
9.
Exp Neurol ; 195(1): 27-39, 2005 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-15944136

RESUMO

Lewy bodies (LB) are a pathological hallmark of Parkinson's disease (PD). Whether LBs are neuroprotective, cytotoxic, or an age-related epiphenomenon is still debated. In the present study, the genetic fingerprints of mesencephalic dopaminergic (DA) neurons containing LBs versus mesencephalic DA neurons not containing LBs were compared in five PD patients. Total RNA from single neurons of both neuronal subpopulations was obtained by immuno-laser capture microdissection. Subsequently, RNA arbitrarily primed PCR was employed to generate expression profiles from the extracted RNA. Differentially displayed polymorphic fragments were dissected from silver-stained polyacrylamide gels. Most of these expressed sequence tags (ESTs) were homologous to known human sequences (56/64, 87.5%). Based on the potential significance of individual ESTs in neurodegenerative disorders, 5 ESTs of interest were selected for further quantitative expression analysis by real-time quantitative reverse transcription PCR (rtq RT-PCR). DA neurons without LBs preferentially expressed molecules beneficial for cell survival, whereas genes preferentially expressed in DA neurons containing LBs may support a cytotoxic role of LBs. Thus, we favor the view that LB-positive DA neurons are sicker than their LB-negative counterparts, and that inhibition of LB formation may indeed represent a therapeutic strategy in PD.


Assuntos
Perfilação da Expressão Gênica , Corpos de Lewy/genética , Neurônios/patologia , Doença de Parkinson/genética , Idoso , Northern Blotting , Impressões Digitais de DNA/métodos , Dopamina/metabolismo , Feminino , Humanos , Imuno-Histoquímica/métodos , Corpos de Lewy/patologia , Masculino , Mesencéfalo/patologia , Pessoa de Meia-Idade , Doença de Parkinson/patologia , Mudanças Depois da Morte , RNA Mensageiro/biossíntese , Reação em Cadeia da Polimerase Via Transcriptase Reversa/métodos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA